scholarly journals Real-world weight change among patients treated with glucagon-like peptide-1 receptor agonist, dipeptidyl peptidase-4 inhibitor and sulfonylureas for type 2 diabetes and the influence of medication adherence

2017 ◽  
Vol 3 (3) ◽  
pp. 342-351 ◽  
Author(s):  
G. S. Carls ◽  
R. Tan ◽  
J. Y. Zhu ◽  
E. Tuttle ◽  
J. Yee ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Medication Adherence ◽  
Real World ◽  
Weight Change ◽  
Receptor Agonist ◽  
Dipeptidyl Peptidase 4 ◽  
Dipeptidyl Peptidase 4 Inhibitor ◽  
Glucagon Like Peptide ◽  
Glucagon Like Peptide 1

Is glucagon-like peptide-1 fully protected by the dipeptidyl peptidase 4 inhibitor sitagliptin when administered to patients with type 2 diabetes?

2018 ◽  
Vol 20 (8) ◽  
pp. 1937-1943 ◽  
Author(s):  
Emilie S. Andersen ◽  
Asger Lund ◽  
Jonatan I. Bagger ◽  
Camilla Andreasen ◽  
Magnus F. Grøndahl ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Dipeptidyl Peptidase ◽  
Dipeptidyl Peptidase 4 ◽  
Dipeptidyl Peptidase 4 Inhibitor ◽  
Glucagon Like Peptide ◽  
Glucagon Like Peptide 1

938-P: The Relationship between Timing of Initiation on a Glucagon-Like Peptide-1 Receptor Agonist and HbA1c among Patients with Type 2 Diabetes

Diabetes ◽  
2020 ◽  
Vol 69 (Supplement 1) ◽  
pp. 938-P
Author(s):  
RALEIGH E. MALIK ◽  
REEMA MODY ◽  
MAUREEN J. LAGE ◽  
KRISTINA BOYE
Keyword(s):  
Type 2 Diabetes ◽  
Receptor Agonist ◽  
Glucagon Like Peptide ◽  
Glucagon Like Peptide 1 ◽  
Timing Of Initiation ◽  
The Relationship
Sign in / Sign up

Export Citation Format

Share Document